Suppr超能文献

注射用、芬戈莫德和富马酸二甲酯治疗多发性硬化症纵向 DTI 指标的稳定性。

Stability of longitudinal DTI metrics in MS with treatment of injectables, fingolimod and dimethyl fumarate.

机构信息

School of Health Sciences, University of Newcastle College of Health, Medicine and Wellbeing, Callaghan, NSW, Australia.

Hunter Medical Research Institute, New Lambton Heights, NSW, Australia.

出版信息

Neuroradiol J. 2023 Aug;36(4):388-396. doi: 10.1177/19714009221140511. Epub 2022 Nov 17.

Abstract

BACKGROUND AND PURPOSE

Diffusion MRI (dMRI) is sensitive to microstructural changes in white matter of people with relapse-remitting multiple sclerosis (pw-RRMS) that lead to progressive disability. The role of diffusion in assessing the efficacy of different therapies requires more investigation. This study aimed to evaluate selected dMRI metrics in normal-appearing white matter and white matter-lesion in pw-RRMS and healthy controls longitudinally and compare the effect of therapies given.

MATERIAL AND METHODS

Structural and dMRI scans were acquired from 78 pw-RRMS (29 injectables, 36 fingolimod, 13 dimethyl fumarate) and 43 HCs at baseline and 2-years follow-up. Changes in dMRI metrics and correlation with clinical parameters were evaluated.

RESULTS

Differences were observed in most clinical parameters between pw-RRMS and HCs at both timepoints ( ≤ 0.01). No significant differences in average changes over time were observed for any dMRI metric between treatment groups in either tissue type. Diffusion metrics in NAWM and WML correlated negatively with most cognitive domains, while FA correlated positively at baseline but only for NAWM at follow-up ( ≤ 0.05). FA correlated negatively with disability in NAWM and WML over time, while MD and RD correlated positively only in NAWM.

CONCLUSIONS

This is the first DTI study comparing the effect of different treatments on dMRI parameters over time in a stable cohort of pw-RRMS. The results suggest that brain microstructural changes in a stable MS cohort are similar to HCs independent of the therapies used.

摘要

背景与目的

弥散磁共振成像(dMRI)对缓解-复发型多发性硬化症(pw-RRMS)患者白质的微观结构变化敏感,这些变化会导致进行性残疾。评估不同治疗方法效果的扩散作用需要更多的研究。本研究旨在评估 pw-RRMS 和健康对照者正常表现白质和白质病变中选定的 dMRI 指标,并进行纵向比较,以评估不同治疗方法的效果。

材料与方法

在基线和 2 年随访时,从 78 名 pw-RRMS(29 名注射剂、36 名芬戈莫德、13 名二甲基富马酸)和 43 名 HC 中采集结构和 dMRI 扫描。评估 dMRI 指标的变化及其与临床参数的相关性。

结果

在两个时间点( ≤ 0.01),pw-RRMS 和 HC 之间的大多数临床参数都存在差异。在任何组织类型中,不同治疗组之间的任何 dMRI 指标在平均变化上均未观察到随时间的显著差异。NAWM 和 WML 的弥散指标与大多数认知域呈负相关,而 FA 在基线时呈正相关,但仅在随访时对 NAWM 呈正相关( ≤ 0.05)。FA 与 NAWM 和 WML 随时间推移的残疾呈负相关,而 MD 和 RD 仅在 NAWM 中呈正相关。

结论

这是第一项在稳定的 pw-RRMS 队列中比较不同治疗方法对 dMRI 参数随时间变化的影响的 DTI 研究。结果表明,稳定 MS 队列中的脑微观结构变化与 HC 相似,与使用的治疗方法无关。

相似文献

1
Stability of longitudinal DTI metrics in MS with treatment of injectables, fingolimod and dimethyl fumarate.
Neuroradiol J. 2023 Aug;36(4):388-396. doi: 10.1177/19714009221140511. Epub 2022 Nov 17.
2
Neural diffusion tensor imaging metrics correlate with clinical measures in people with relapsing-remitting MS.
Neuroradiol J. 2022 Oct;35(5):592-599. doi: 10.1177/19714009211067400. Epub 2022 Feb 4.
4
Fingolimod treatment reverses signs of diffuse white matter damage in multiple sclerosis: A pilot study.
Mult Scler Relat Disord. 2021 Feb;48:102690. doi: 10.1016/j.msard.2020.102690. Epub 2020 Dec 15.
8
The heterogeneity of tissue destruction between iron rim lesions and non-iron rim lesions in multiple sclerosis: A diffusion MRI study.
Mult Scler Relat Disord. 2022 Oct;66:104070. doi: 10.1016/j.msard.2022.104070. Epub 2022 Jul 26.
9
Multimodal MRI Response to Fingolimod in Multiple Sclerosis: A Nonrandomized, Single Arm, Observational Study.
J Neuroimaging. 2021 Mar;31(2):379-387. doi: 10.1111/jon.12824. Epub 2020 Dec 26.

引用本文的文献

1

本文引用的文献

2
Myelin imaging measures as predictors of cognitive impairment in MS patients: A hybrid PET-MRI study.
Mult Scler Relat Disord. 2022 Jan;57:103331. doi: 10.1016/j.msard.2021.103331. Epub 2021 Oct 13.
3
Neural diffusion tensor imaging metrics correlate with clinical measures in people with relapsing-remitting MS.
Neuroradiol J. 2022 Oct;35(5):592-599. doi: 10.1177/19714009211067400. Epub 2022 Feb 4.
4
Fingolimod treatment reverses signs of diffuse white matter damage in multiple sclerosis: A pilot study.
Mult Scler Relat Disord. 2021 Feb;48:102690. doi: 10.1016/j.msard.2020.102690. Epub 2020 Dec 15.
5
Changes in structural and functional connectivity during two years of fingolimod therapy for multiple sclerosis.
Magn Reson Imaging. 2020 Dec;74:113-120. doi: 10.1016/j.mri.2020.09.015. Epub 2020 Sep 19.
6
Comparing MRI metrics to quantify white matter microstructural damage in multiple sclerosis.
Hum Brain Mapp. 2019 Jul;40(10):2917-2932. doi: 10.1002/hbm.24568. Epub 2019 Mar 19.
7
Diffusion tensor imaging and disability progression in multiple sclerosis: A 4-year follow-up study.
Brain Behav. 2019 Jan;9(1):e01194. doi: 10.1002/brb3.1194. Epub 2018 Dec 26.
8
Multiple sclerosis: clinical aspects.
Curr Opin Neurol. 2018 Dec;31(6):752-759. doi: 10.1097/WCO.0000000000000622.
9
Brain microstructural injury occurs in patients with RRMS despite 'no evidence of disease activity'.
J Neurol Neurosurg Psychiatry. 2018 Sep;89(9):977-982. doi: 10.1136/jnnp-2017-317606. Epub 2018 Mar 16.
10
Emerging Understanding of the Mechanism of Action for Dimethyl Fumarate in the Treatment of Multiple Sclerosis.
Front Neurol. 2018 Jan 23;9:5. doi: 10.3389/fneur.2018.00005. eCollection 2018.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验